1
|
Rademacher J, Ringshausen FC, Suhling H, Fuge J, Marsch G, Warnecke G, Haverich A, Welte T, Gottlieb J. Lung transplantation for non-cystic fibrosis bronchiectasis. Respir Med 2016; 115:60-5. [PMID: 27215505 DOI: 10.1016/j.rmed.2016.04.007] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/25/2015] [Revised: 04/04/2016] [Accepted: 04/17/2016] [Indexed: 12/31/2022]
Abstract
BACKGROUND Lung transplantation (LTx) is a well-established treatment for end-stage pulmonary disease. However, data regarding microbiology and outcome of patients with non-cystic fibrosis bronchiectasis (NCFB) after lung transplantation are limited. METHODS A retrospective analysis between August 1992 and September 2014 of all patients undergoing lung transplantation at our program of all recipients with a primary diagnosis of bronchiectasis was performed. Microbiology of sputum and bronchoalveolar lavage specimens, lung function and clinical parameters pre- and post-LTx were assessed retrospectively. Overall survival was compared to the total cohort of lung transplant recipients at institution. The survival and development of chronic lung allograft dysfunction (CLAD) was compared in patients with and without chronic Pseudomonas aeruginosa (PSA) infection after LTx. RESULTS 34 patients were transplanted. Median age at transplantation was 40 (IQR 33-52) years. The most common etiologies of bronchiectasis were idiopathic (41%), chronic obstructive pulmonary disease (COPD) (21%) and post-infectious (15%). The most common organism of pre- and posttransplant chronic airway infection was PSA. One-year Kaplan-Meier survival for patients with bronchiectasis was 85% and 5-year survival was 73% and similar to the entire cohort. All three patients with an associated diagnosis of immunodeficiency died due to infection and sepsis within the first year. Patients with persistent colonization with Pseudomonas aeruginosa after transplantation had worse long-term survival by trend and developed chronic lung allograft dysfunction more frequently. CONCLUSIONS Overall survival of patients with bronchiectasis after LTx is comparable to other underlying diseases. A reduced survival was observed in patients with the underlying diagnosis of immunodeficiency.
Collapse
Affiliation(s)
- Jessica Rademacher
- Dept. of Respiratory Medicine, Hannover Medical School, Carl- Neuberg Str. 1, Hannover, Germany.
| | - Felix C Ringshausen
- Dept. of Respiratory Medicine, Hannover Medical School, Carl- Neuberg Str. 1, Hannover, Germany; BREATH, Biomedical Research in End-stage and Obstructive Lung Disease, Hannover Medical School, Member of the German Center for Lung Research (DZL), Carl- Neuberg Str. 1, Germany
| | - Hendrik Suhling
- Dept. of Respiratory Medicine, Hannover Medical School, Carl- Neuberg Str. 1, Hannover, Germany
| | - Jan Fuge
- BREATH, Biomedical Research in End-stage and Obstructive Lung Disease, Hannover Medical School, Member of the German Center for Lung Research (DZL), Carl- Neuberg Str. 1, Germany
| | - Georg Marsch
- Dept. of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Carl- Neuberg Str. 1, Hannover, Germany
| | - Gregor Warnecke
- BREATH, Biomedical Research in End-stage and Obstructive Lung Disease, Hannover Medical School, Member of the German Center for Lung Research (DZL), Carl- Neuberg Str. 1, Germany; Dept. of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Carl- Neuberg Str. 1, Hannover, Germany
| | - Axel Haverich
- BREATH, Biomedical Research in End-stage and Obstructive Lung Disease, Hannover Medical School, Member of the German Center for Lung Research (DZL), Carl- Neuberg Str. 1, Germany; Dept. of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Carl- Neuberg Str. 1, Hannover, Germany
| | - Tobias Welte
- Dept. of Respiratory Medicine, Hannover Medical School, Carl- Neuberg Str. 1, Hannover, Germany; BREATH, Biomedical Research in End-stage and Obstructive Lung Disease, Hannover Medical School, Member of the German Center for Lung Research (DZL), Carl- Neuberg Str. 1, Germany
| | - Jens Gottlieb
- Dept. of Respiratory Medicine, Hannover Medical School, Carl- Neuberg Str. 1, Hannover, Germany; BREATH, Biomedical Research in End-stage and Obstructive Lung Disease, Hannover Medical School, Member of the German Center for Lung Research (DZL), Carl- Neuberg Str. 1, Germany
| |
Collapse
|
2
|
Rozé H, Thumerel M, Barandon L, Dromer C, Perrier V, Jougon J, Velly JF, Ouattara A. Cardiopulmonary Bypass During a Second-Lung Implantation Improves Postoperative Oxygenation After Sequential Double-Lung Transplantation. J Cardiothorac Vasc Anesth 2013; 27:467-73. [DOI: 10.1053/j.jvca.2012.11.005] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/05/2012] [Indexed: 11/11/2022]
|
3
|
Henri C, Giraldeau G, Dorais M, Cloutier AS, Girard F, Noiseux N, Ferraro P, Rinfret S. Atrial fibrillation after pulmonary transplantation: incidence, impact on mortality, treatment effectiveness, and risk factors. Circ Arrhythm Electrophysiol 2011; 5:61-7. [PMID: 22157520 DOI: 10.1161/circep.111.964569] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Atrial fibrillation (AF) is common after thoracic surgery. Limited data exist concerning the incidence of AF, its impact on mortality, the effectiveness of therapy, and the risk factors of AF after pulmonary transplantation. METHODS AND RESULTS We reviewed the medical files of 224 consecutive lung transplant recipients who underwent surgery over a 10-year period at a large Canadian center. We collected patient characteristics, in-hospital treatments, and outcomes. Time-to-event analysis was used to account for in-hospital follow-up and models generated to assess the impact of AF on mortality and independent risk factors of AF after transplantation. Postoperative AF occurred in 65 patients (29%). AF was more likely to occur with complications such as pneumonia, mediastinitis, and bronchial dehiscence and was not an independent risk factor of mortality (hazard ratio=1.56; 95% confidence interval, 0.52-4.63). Pharmacological or electric therapy for rhythm or rate control of AF was administered to 97% of patients. Intravenous amiodarone was used in 46%, electric cardioversion in 28%, and heparin in 26%. Only 1 patient remained in AF at discharge. Age (hazard ratio=1.08 by year; 95% confidence interval, 1.05-1.12), bilateral transplantation (hazard ratio=1.87; 95% confidence interval, 1.03-3.42), and a history of AF before the transplantation (hazard ratio=4.48; 95% confidence interval, 1.05-19.11) were found to be independently associated with an increased incidence of postoperative AF. CONCLUSIONS AF is fairly common after pulmonary transplantation, transient, and relatively benign. It is not independently associated with increased in-hospital mortality. Most patients return to sinus rhythm before discharge. Age, prior AF, and bilateral transplantation increase the risk of postoperative AF.
Collapse
Affiliation(s)
- Christine Henri
- Adult Cardiology Program, University of Montreal, Montreal, Canada
| | | | | | | | | | | | | | | |
Collapse
|
4
|
A Comparison of Atrial Arrhythmias After Heart or Double-Lung Transplantation at a Single Center. J Am Coll Cardiol 2009; 54:2043-8. [DOI: 10.1016/j.jacc.2009.08.029] [Citation(s) in RCA: 60] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/04/2009] [Revised: 08/19/2009] [Accepted: 08/24/2009] [Indexed: 11/19/2022]
|
5
|
|
6
|
Al-Kattan KM, Essa MA, Hajjar WM, Ashour MH, Saleh WN, Rafay MA. Surgical results for bronchiectasis based on hemodynamic (functional and morphologic) classification. J Thorac Cardiovasc Surg 2005; 130:1385-90. [PMID: 16256793 DOI: 10.1016/j.jtcvs.2005.06.026] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/29/2005] [Revised: 05/20/2005] [Accepted: 06/30/2005] [Indexed: 11/18/2022]
Abstract
OBJECTIVE This study was a prospective evaluation of surgical indications and outcomes for unilateral and bilateral bronchiectasis according to hemodynamic (functional and morphologic) classification. METHODS Between January 1998 and January 2004, the morphologic features (cystic versus cylindric) by chest computed tomography and the hemodynamic features (perfused versus nonperfused) by lung ventilation/perfusion scan were determined in 66 patients with bronchiectasis (53 unilateral and 13 bilateral). The indication for surgical resection in both groups was the presence of localized areas of cystic, nonperfused bronchiectasis. RESULTS In the unilateral bronchiectasis group, there were 28 female and 25 male patients with an average age of 37.5 +/- 3.8 years (range 6-40 years). Pneumonectomy was performed in 10 cases (8 left and 2 right), and lobectomy or bilobectomy was performed in 43. In the bilateral group, there were 7 male and 6 female patients with an average age of 42 +/- 5.4 years (range 9-55 years). Pneumonectomy was performed in 2 cases, lobectomy in 5, and bilateral staged lobectomy in 6. There was 1 postoperative death (1.5%), and morbidity was 18% (12 patients). Four patients required reexploration for bleeding, 4 had prolonged air leak develop, 3 acquired pulmonary infections, and 1 had localized empyema develop. During a mean follow-up of 52 months (range 24-82 months), 48 patients were considered cured (73%) and 17 had symptomatic improvement (26%). Pseudomonas infection and underlying chronic obstructive airway disease were poor prognostic factors (P < .05). CONCLUSION The hemodynamic (functional and morphologic) classification provides an accurate functional classification for bronchiectasis. Its application in determining the indications and extent of surgical resection is superior to morphologic classification alone. Curative resection can be achieved in both unilateral and bilateral bronchiectasis with acceptable morbidity.
Collapse
Affiliation(s)
- Khaled M Al-Kattan
- Division of Thoracic Surgery, Department of Surgery, King Khalid University Hospital, Riyadh, Saudi Arabia.
| | | | | | | | | | | |
Collapse
|
7
|
Nathan JA, Sharples LD, Exley AR, Sivasothy P, Wallwork J. The Outcomes of Lung Transplantation in Patients With Bronchiectasis and Antibody Deficiency. J Heart Lung Transplant 2005; 24:1517-21. [PMID: 16210124 DOI: 10.1016/j.healun.2004.11.013] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2004] [Revised: 10/15/2004] [Accepted: 11/12/2004] [Indexed: 11/20/2022] Open
Abstract
BACKGROUND Lung transplantation is an established treatment for end-stage bronchiectasis. A proportion of patients with bronchiectasis have an associated antibody deficiency. This group benefits from immunoglobulin replacement therapy, but the outcome of lung transplantation is not known. METHODS We conducted a retrospective observational study of all who received a transplant for bronchiectasis at our unit. We compared the survival after transplant, number of infective and rejection episodes, and the change in forced expiratory volume in 1 second (FEV1). RESULTS Five of the 37 patients identified with bronchiectasis had an antibody deficiency that required immunoglobulin replacement therapy. Actuarial survival was similar in the 2 groups, being 81% at 12 months in the Bronchiectasis Group and 80% in the Antibody Deficiency Group. The FEV1 at 12 months after transplantation was similar in each group, with a predicted mean +/- SD FEV1 of 83.7% +/- 24.2% in those with bronchiectasis and 83.0% +/- 30.4% in those with antibody deficiency as well. The infection and rejection rates in the first year after transplantation were lower in the Antibody Deficiency Group. Infection episodes per 100 patient-days for bronchiectasis alone were 0.90 vs 0.53 and rejection episodes per 100 patient-days were 0.59 vs 0.24. CONCLUSIONS There was no evidence that transplant recipients with bronchiectasis and antibody deficiency have a worse prognosis than those with bronchiectasis alone.
Collapse
Affiliation(s)
- James A Nathan
- Papworth Hospital NHS Trust, Papworth Everard, Cambridge, United Kingdom.
| | | | | | | | | |
Collapse
|
8
|
Beirne PA, Banner NR, Khaghani A, Hodson ME, Yacoub MH. Lung Transplantation for Non-Cystic Fibrosis Bronchiectasis: Analysis of a 13-Year Experience. J Heart Lung Transplant 2005; 24:1530-5. [PMID: 16210126 DOI: 10.1016/j.healun.2004.12.114] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2004] [Revised: 12/15/2004] [Accepted: 12/21/2004] [Indexed: 10/25/2022] Open
Abstract
BACKGROUND Lung transplantation is a well-established treatment for end-stage cystic fibrosis, and there are considerable data on medium- and long-term results. However, less information exists about transplantation for non-cystic fibrosis bronchiectasis. METHODS Between December 1988 and June 2001, 22 patients (12 men, 10 women) underwent transplantation for bronchiectasis not due to cystic fibrosis. Procedures were bilateral sequential single-lung transplants (BSSLTX) in 4 patients, en bloc double lung transplants (DLTX) in 5, heart-lung transplants (HLTX) in 6, and single-lung transplants (SLTX) in 7. Lifelong outpatient follow-up was continued at a minimum of every 6 months. RESULTS One-year Kaplan-Meier survival for all patients was 68% (95% confidence interval [CI], 54%-91%), and 5-year survival was 62% (95% CI, 41-83%). One-year survival after SLTX was 57% (95% CI, 20%-94%) vs 73% (95% CI, 51-96%) for those receiving 2 lungs. At 6 months, mean forced expiratory volume in 1 second was 73% predicted (range, 58%-97%), and mean forced vital capacity was 68% predicted (range, 53%-94%) after receiving 2 lungs (n = 10); in the SLTX group at 6 months, mean forced expiratory volume in 1 second was 50% predicted (range, 34%-61%), and mean forced vital capacity was 53% predicted (range 46-63%) (n = 4). CONCLUSIONS Survival and lung function after transplantation for non-cystic fibrosis bronchiectasis was similar to that after transplantation for cystic fibrosis. A good outcome is possible after single lung transplantation in selected patients.
Collapse
Affiliation(s)
- Paul Adrian Beirne
- Royal Brompton and Harefield Hospital, Harefield, Middlesex, United Kingdom.
| | | | | | | | | |
Collapse
|
9
|
Curtis HJ, Bourke SJ, Dark JH, Corris PA. Lung Transplantation Outcome in Cystic Fibrosis Patients With Previous Pneumothorax. J Heart Lung Transplant 2005; 24:865-9. [PMID: 15982615 DOI: 10.1016/j.healun.2004.05.024] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2003] [Revised: 03/29/2004] [Accepted: 05/14/2004] [Indexed: 11/20/2022] Open
Abstract
BACKGROUND High perioperative mortality that results from hemorrhage from pleural adhesions was reported in the early experience of heart-lung transplantation. This led to previous pleural procedures becoming a relative/absolute contraindication to transplantation in some centers, despite the advent of bilateral lung transplantation. Has this lead to a more conservative approach to pneumothorax management in patients with cystic fibrosis (CF)? And what is the effect of previous pleural procedures on surgical outcome of lung transplantation? METHODS We reviewed 3 groups of patients transplanted at this center from 1989 to 2002, matched for year of lung transplantation. Group A comprised 16 patients with CF with a history of previous pneumothorax with or without pleural procedure. Group B comprised 16 patients with CF with no history of pneumothorax. Group C comprised 16 noninflammatory/nonbronchiectatic patients with no history of pneumothorax. Measured outcomes included blood products provided intraoperatively; operation and cardiopulmonary bypass times; postoperative hemorrhage; times to extubation, discharge from the intensive care unit and hospital discharge; forced expiratory volume at 1 second at 6 months; 30-day mortality; pleural adhesions graded descriptively; and previous pneumothorax management (Group A only). There were 35 pneumothorax episodes in the 16 patients in Group A. Nine episodes were managed with observation alone. Nine patients required invasive management, 25 chest drains were placed, 3 patients received medical pleurodesis, and 2 underwent thoracic surgical intervention. RESULTS No significant difference was observed between the 3 groups regarding blood products intraoperatively or duration of procedure. Pleural adhesions found at operation were significantly more in Group A, with dense adhesions found only in Group A (p<0.05). Group C was significantly more likely to be free from adhesions, with 13 patients clear (p<0.01 Group C vs Group A, Group C vs Group B). No statistically significant difference was found in the other measured parameters. CONCLUSIONS Pneumothorax is treated conservatively in a potential lung transplant population. Patients with CF and previous pneumothorax with or without pleural procedures undergoing lung transplantation have dense pleural adhesions; however, this does not affect surgical outcome significantly. Patients with emphysema, fibrosing alveolitis, or obliterative bronchiolitis were significantly more likely to be free of pleural adhesions, suggesting that the inflammatory/chronic infective component of CF independently contributes to the increased pleural adhesions. Previous pleural procedures for pneumothorax should not be considered a contraindication in the assessment of suitability for lung transplantation.
Collapse
Affiliation(s)
- Helen Jane Curtis
- Transplantation and Immunobiology Research Group, University of Newcastle Upon Tyne and Freeman Hospital, Newcastle Upon Tyne, United Kingdom.
| | | | | | | |
Collapse
|
10
|
De Soyza A, Morris K, McDowell A, Doherty C, Archer L, Perry J, Govan JRW, Corris PA, Gould K. Prevalence and clonality of Burkholderia cepacia complex genomovars in UK patients with cystic fibrosis referred for lung transplantation. Thorax 2004; 59:526-8. [PMID: 15170040 PMCID: PMC1747049 DOI: 10.1136/thx.2003.010801] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BACKGROUND It has previously been reported that patients infected with Burkholderia cenocepacia (genomovar III) before lung transplantation have a poorer outcome than those with other B. cepacia complex infections. METHODS An extensive study was conducted to determine the prevalence and clonality of B. cepacia complex genomovars isolated from patients referred for transplant assessment between 1989 to the present and, where appropriate, whether strain type was related to transplant outcome. RESULTS Isolates from 29 patients were identified as B. cepacia complex organisms by molecular analysis. Thirteen patients (45%) were infected with the highly transmissible ET-12 strain of B. cenocepacia recA lineage III-A, while all remaining patients were infected with genetically unique B. cenocepacia, B. multivorans, and B. vietnamiensis strains. All previously reported deaths following transplantation were associated with ET-12 infection. CONCLUSIONS The ET-12 strain is the predominant cause of B. cenocepacia infections in patients with cystic fibrosis referred to our pulmonary transplant centre and is associated with poor transplant outcomes using standard treatment regimens.
Collapse
Affiliation(s)
- A De Soyza
- Transplantation and Immunobiology Group, The Freeman Hospital, High Heaton, Newcastle upon Tyne NE7 7DN, UK.
| | | | | | | | | | | | | | | | | |
Collapse
|
11
|
De Soyza A, Archer L, Wardle J, Parry G, Dark JH, Gould K, Corris PA. Pulmonary transplantation for cystic fibrosis: pre-transplant recipient characteristics in patients dying of peri-operative sepsis. J Heart Lung Transplant 2003; 22:764-9. [PMID: 12873544 DOI: 10.1016/s1053-2498(02)00641-1] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
BACKGROUND Pulmonary transplantation has emerged as a successful treatment for end-stage cystic fibrosis. Despite the chronic bronchial sepsis and often multi-resistant organisms seen in this group of recipients, death due to post-operative sepsis is relatively scarce. Identifying potential recipient risk factors for poor outcome may further improve the utilization of a scarce donor pool. METHODS We assessed the role of pre-operative clinical measures of sepsis, microbial characteristics and recipient characteristics on post-transplant outcome in 85 cystic fibrosis patients who underwent pulmonary transplantation. Ten percent of patients died in the early post-operative period due to sepsis. The prognostic role of recipient factors including markers of sepsis, such as white cells and C-reactive protein (CRP), and the influence of multi-resistant organisms, in particular organisms from the Burkholderia cepacia complex, on outcomes were investigated. RESULTS We found no prognostic effect of gender, pre-transplant CRP, forced expiratory volume in 1 second (FEV(1)), weight, diabetic status or infection with multi-resistant Pseudomonas organisms. A raised white cell count or temperature or a pre-transplant infection with B cepacia was, however, associated with a significantly poorer prognosis at p = 0.03, 0.03 and 0.001, respectively. CONCLUSIONS Pre-operative B cepacia complex infection, leukocytosis and pyrexia, but not CRP, weight, diabetes or lung function, were found to be associated with poorer post-transplant outcome. The most clinically relevant of these to the subsequent risk of post-operative death from sepsis appear to be B cepacia infection and pyrexia.
Collapse
Affiliation(s)
- Anthony De Soyza
- Lung Transplantation and Biology, The Freeman Hospital, University of Newcastle, Newcastle, UK.
| | | | | | | | | | | | | |
Collapse
|
12
|
Ward C, Cámara M, Forrest I, Rutherford R, Pritchard G, Daykin M, Hardman A, de Soyza A, Fisher AJ, Williams P, Corris PA. Preliminary findings of quorum signal molecules in clinically stable lung allograft recipients. Thorax 2003; 58:444-6. [PMID: 12728169 PMCID: PMC1746678 DOI: 10.1136/thorax.58.5.444] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BACKGROUND Infection with bacteria such as Pseudomonas is common in lung allograft recipients, particularly during chronic rejection. Analysis of sputum samples from patients with cystic fibrosis infected with Pseudomonas aeruginosa or Burkholderia cepacia has indicated the presence of bacterial N-acylhomoserine lactones (AHLs) quorum sensing signalling molecules. AHLs not only control the expression of bacterial virulence genes but are also involved in stimulating the maturation of antibiotic resistant biofilms and host chemokine release. It was hypothesised that AHLs may be detected even in clinically stable lung transplant recipients free of clinical infection or rejection. METHODS Three 60 ml samples of bronchoalveolar lavage (BAL) fluid were taken from nine stable lung transplant recipients 3-12 months after transplantation. Detection of AHLs was carried out on dichloromethane extracted supernatants using the bioluminescence based AHL reporter plasmid pSB1075. This responds to the presence of AHLs with long acyl chains (C10-C14), generating light. Synthetic AHLs were included as positive controls. RESULTS Five of the nine BAL fluid supernatants exhibited AHL activity, suggesting the presence of AHLs with long N-acyl chains. There was no correlation between the levels of AHLs detected or their absence and BAL fluid microbiology or diagnosis before transplantation. CONCLUSIONS This is the first evidence for the presence of AHL quorum sensing signals in human lung allograft recipients, even in subjects with no rejection or apparent infection. Further longitudinal follow up of these preliminary findings is required to elucidate potential links with infection, rejection, and allograft deterioration.
Collapse
Affiliation(s)
- C Ward
- ImmunoBiology and Transplantation Group, University of Newcastle upon Tyne and The Freeman Hospital, Newcastle upon Tyne NE7 7DN, UK.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Mazières J, Murris M, Didier A, Giron J, Dahan M, Berjaud J, Léophonte P. Limited operation for severe multisegmental bilateral bronchiectasis. Ann Thorac Surg 2003; 75:382-7. [PMID: 12607644 DOI: 10.1016/s0003-4975(02)04322-9] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
BACKGROUND Some patients exhibiting severe multisegmental bilateral bronchiectasis are no longer improved with antibiotic treatment and drainage and, most of the time, operation is contraindicated. In our institution, limited operation has been offered to select patients for this indication. We report our data regarding the feasibility and utility of such a procedure. METHODS We studied 16 patients who underwent surgical removal of nonlocalized disease between 1990 and 1999. We report the mortality and morbidity rates of this surgical procedure and the clinical, bacteriological, and functional data for each patient. RESULTS There was no mortality and the morbidity was low (18%, all with favorable outcome). Symptoms such as hemoptysis, sputum production, or dyspnea were also improved. The recurring infections decreased in frequency in 8 patients and disappeared completely in 5 others. The bacteriological data assessment revealed disappearance of germs in 4 patients and persistence of chronic colonization in others. Postoperative spirometric data were not worsened and postoperative computed tomographic scans did not show progression of lesions not removed. CONCLUSIONS These results suggest that, in properly selected patients, lasting symptomatic improvement can be achieved by resection. Limited operation may be indicated in nonlocalized bilateral bronchiectasis, provided that a target can be identified. This procedure is supported by physiopathologic arguments and is particularly relevant to patients with bronchiectasis with cystic and functionless territories.
Collapse
Affiliation(s)
- Julien Mazières
- Department of Pulmonary Diseases, Rangueil Hospital, University of Toulouse, Toulouse, France.
| | | | | | | | | | | | | |
Collapse
|
14
|
|
15
|
Barlow CW, Robbins RC, Moon MR, Akindipe O, Theodore J, Reitz BA. Heart-lung versus double-lung transplantation for suppurative lung disease. J Thorac Cardiovasc Surg 2000; 119:466-76. [PMID: 10694605 DOI: 10.1016/s0022-5223(00)70125-5] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
OBJECTIVE The purpose of this study was to compare outcomes after heart-lung or double-lung transplantation in patients undergoing transplantation because of end-stage suppurative lung disease. METHODS We reviewed our experience in patients with cystic fibrosis or bronchiectasis who had heart-lung or double-lung transplantation between January 1988 and September 1997. Twenty-three patients (14 male, 21 cystic fibrosis) had heart-lung transplantation and 24 patients (8 male, 19 cystic fibrosis) had double-lung transplantation. There were no statistically significant differences between the groups in age, weight, preoperative creatinine level, cytomegalovirus status, maintenance immunosuppression, or donor demographics. Patients received induction therapy with monoclonal (OKT3) or polyclonal (rabbit anti-thymocyte globulin) antibody. RESULTS Sixteen of 24 patients had double-lung transplantation after 1994 whereas 13 of 22 patients had heart-lung transplantation before 1991, allowing longer follow-up for the heart-lung group. Mean waiting times for transplantation were 270 +/- 245 days (heart-lung) and 361 +/- 229 days (double-lung; P =.20). The 1-, 3-, and 5-year actuarial survival figures were respectively 86%, 82%, and 65% (heart-lung) and 96%, 75%, and unavailable (double-lung; P = no significant difference). The 1-, 3-, and 5-year rates of freedom from obliterative bronchiolitis were respectively 77%, 61%, and 45% (heart-lung) and 86%, 78%, and unavailable (double-lung; P = no significant difference). Linearized overall infection rates (events/100 patient-days) were 2.05 +/- 0.33 (heart-lung) and 2.34 +/- 0.34 (double-lung; P = NS) at 3 months. Thirty-day survival was 100% (heart-lung) and 96% (double-lung). There were 7 late deaths among heart-lung recipients (3 obliterative bronchiolitis, 2 infection, 0 graft coronary artery disease, 2 other) whereas 2 late deaths related to obliterative bronchiolitis occurred in double-lung recipients. Graft coronary artery disease (all stenoses < 50%) affected 15% of heart-lung survivors, whereas 3 double-lung recipients (12.5%) required either bronchial dilatation or stenting. CONCLUSION Heart-lung and double-lung transplantation provide similar palliation for patients with end-stage suppurative lung disease. Therefore double-lung transplantation should be the preferred operation for most patients with end-stage suppurative lung disease.
Collapse
Affiliation(s)
- C W Barlow
- Falk Cardiovascular Research Center, Stanford University School of Medicine, Stanford, CA 94305-5407, USA
| | | | | | | | | | | |
Collapse
|
16
|
Hoskins G, McCowan C, Neville RG, Thomas GE, Smith B, Silverman S. Risk factors and costs associated with an asthma attack. Thorax 2000; 55:19-24. [PMID: 10607797 PMCID: PMC1745605 DOI: 10.1136/thorax.55.1.19] [Citation(s) in RCA: 118] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BACKGROUND A study was undertaken to identify asthma patients at risk of an attack and to assess the economic impact of treatment strategies. METHODS A retrospective cohort analysis of a representative data set of 12 203 patients with asthma in the UK over a one year period was performed. Logistic multiple regression was used to model the probability of an attack occurring using a set of categorised predictor factors. Health service costs were calculated by applying published average unit costs to the patient resource data. The main outcome measures were attack incidence, health service resource use, drug treatment, and cost estimates for most aspects of asthma related health care. RESULTS Children under five years of age accounted for 597 patients (5%), 3362 (28%) were aged 5-15 years, 4315 (35%) 16-44, 3446 (28%) 45-74, and 483 (4%) were aged over 74 years. A total of 9016 patients (74%) were on some form of prophylactic asthma medication; 2653 (22%) experienced an attack in the year data collection occurred. Overall health care expenditure was estimated at pound2.04 million. The average cost per patient who had an attack was pound381 compared with pound108 for those who did not, an increase of more than 3.5 times. In those aged under five and those over 75 years of age there were no significant markers to identify risk, but both groups were small in size. The level of treatment step in the British Thoracic Society (BTS) asthma guidelines was a statistically significant factor for all other age groups. Night time symptoms were significant in the 5-15, 16-44 and 45-74 age groups, exercise induced symptoms were only significant for the 5-15 age group, and poor inhaler technique in the 16-44 age group. CONCLUSIONS Patients at any treatment step of the BTS asthma guidelines are at risk of an asthma attack, the risk increasing as the treatment step increases. Poorly controlled asthma may have a considerable impact on health care costs. Appropriate targeting of preventive measures could therefore reduce overall health care costs and the growing pressures on hospital services associated with asthma management.
Collapse
Affiliation(s)
- G Hoskins
- Tayside Centre for General Practice, University of Dundee, Kirsty Semple Way, Dundee DD2 4AD, UK
| | | | | | | | | | | |
Collapse
|
17
|
Wittram C, Rappaport DC. Case report: Expiratory helical CT scan minimum intensity projection imaging in cystic fibrosis. Clin Radiol 1998; 53:615-6. [PMID: 9744591 DOI: 10.1016/s0009-9260(98)80157-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Affiliation(s)
- C Wittram
- The Toronto Hospital, University of Toronto, Department of Medical Imaging, Ontario, Canada
| | | |
Collapse
|
18
|
Abstract
Over the last ten to fifteen years medical and surgical advances have led to lower rates of infection and infection-related mortality in transplant recipients. Despite these advances, the process whereby one diagnoses and manages infectious problems in transplant patients has become increasingly complex. Evaluation of transplant patients with infections requires a good understanding of the intricacies of modern immunosuppressive therapy and both the typical and atypical clinical manifestations of many conventional and opportunistic pathogens. In particular, it is incumbent upon the clinicians caring for transplant patients to be familiar with the biology of cytomegalovirus and other herpes viruses, and of the prophylactic strategies that have evolved to lessen the burden of disease from these agents. Thorough knowledge is also required of common fungal pathogens and the viruses that cause chronic hepatitis. Transplant patients also should always be evaluated in the temporal context of their transplant operation, because different diseases are prevalent at different times after transplantation. Since immunosuppressive drugs modify the clinical presentation of infections is important to maintain clinical vigilance and attend to even minor new symptoms. This chapter is designed to provide a relatively concise overview of transplant infections for intensivists or other clinicians who encounter transplant patients in their practice. The references encompass much of the classic transplant infectious disease literature; they are included, not only for citation, but as a bibliography for further study.
Collapse
|